Playback speed
10 seconds
2019 Update on Advanced RCC: Who Needs Treatment, Which 1st Line Drug (Ipi/Nivo, TKI/IO, or TKI Alone), and How to Sequence After 1st Line?
1,548 views
December 16, 2019
Daniel M. Geynisman, MD, Fox Chase Cancer Center, Philadelphia, PA
Dr. Geynisman is an Assistant ...
read more ↘ Professor in the Department of Hematology/Oncology at Fox Chase Cancer Center. He specializes in treating patients with genitourinary malignancies, including prostate, bladder, kidney, testicular, penile and adrenal cancers. Dr. Geynisman has co-authored more than 75 manuscripts in peer-reviewed journals. His research focuses on health outcomes and clinical trials development for genitourinary cancers. He serves on the NCCN guideline panel for testicular cancers and is an assistant editor for Urologic Oncology.
Dr. Geynisman earned his medical degree from the University of Pittsburgh School of Medicine and completed a residency in internal medicine at the University of Pittsburgh Medical Center, serving an additional year as chief resident. He went on to complete a fellowship in hematology/oncology at the University of Chicago, serving as a chief fellow in his final year of training.
↖ read less
Dr. Geynisman is an Assistant ...
read more ↘ Professor in the Department of Hematology/Oncology at Fox Chase Cancer Center. He specializes in treating patients with genitourinary malignancies, including prostate, bladder, kidney, testicular, penile and adrenal cancers. Dr. Geynisman has co-authored more than 75 manuscripts in peer-reviewed journals. His research focuses on health outcomes and clinical trials development for genitourinary cancers. He serves on the NCCN guideline panel for testicular cancers and is an assistant editor for Urologic Oncology.
Dr. Geynisman earned his medical degree from the University of Pittsburgh School of Medicine and completed a residency in internal medicine at the University of Pittsburgh Medical Center, serving an additional year as chief resident. He went on to complete a fellowship in hematology/oncology at the University of Chicago, serving as a chief fellow in his final year of training.
↖ read less
Comments 1
Login to view comments.
Click here to Login
Related Videos
AUTOPLAY